BiotechTube

Olaratumab + Pembrolizumab (KEYTRUDA®)

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Soft Tissue Sarcoma

Conditions

Soft Tissue Sarcoma

Trial Timeline

Jul 3, 2017 → Feb 21, 2023

NCT ID
NCT03126591

About Olaratumab + Pembrolizumab (KEYTRUDA®)

Olaratumab + Pembrolizumab (KEYTRUDA®) is a phase 1 stage product being developed by Eli Lilly for Soft Tissue Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03126591. Target conditions include Soft Tissue Sarcoma.

What happened to similar drugs?

2 of 15 similar drugs in Soft Tissue Sarcoma were approved

Approved (2) Terminated (3) Active (11)
✅daptomycin (up to 14 days)MerckApproved
✅linezolid + vancomycinPfizerApproved
🔄Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
🔄Olaratumab + Doxorubicin + PlaceboEli LillyPhase 3
❌Etoricoxib 60 mg + Etoricoxib 90 mgMerckPhase 3
🔄ridaforolimus + PlaceboMerckPhase 3
🔄Diclofenac sodiumNovartisPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03126591Phase 1Completed

Competing Products

20 competing products in Soft Tissue Sarcoma

See all competitors
ProductCompanyStageHype Score
Olaratumab + Doxorubicin + Ifosfamide + MesnaEli LillyPhase 1
29
Anlotinib HydrochlorideSun PharmaceuticalPhase 2
31
Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
40
Eribulin mesylateEisaiPre-clinical
26
E7389EisaiPhase 2
35
eribulin mesylateEisaiPhase 2
35
Olaratumab + Gemcitabine + Docetaxel + PlaceboEli LillyPhase 1/2
32
LY573636-sodiumEli LillyPhase 2
35
OlaratumabEli LillyPre-clinical
26
Olaratumab + Doxorubicin + PlaceboEli LillyPhase 3
40
Olaratumab + DoxorubicinEli LillyPhase 1
29
Olaratumab + DoxorubicinEli LillyPhase 1
29
Olaratumab + doxorubicinEli LillyPhase 1/2
32
TrabectedinJohnson & JohnsonPre-clinical
26
Doxorubicin + Trabectedin + DexamethasoneJohnson & JohnsonPhase 1
29
Apatinib Mesylate, doxorubicin, ifosfamideJiangsu Hengrui MedicinePhase 2
31
Camrelizumab in Combination With Neoadjuvant ChemotherapyJiangsu Hengrui MedicinePhase 2
31
Durvalumab and Tremelimumab + DoxorubicinAstraZenecaPhase 2
35
Standard arm: Trabectedin in monotherapy + Experimental arm: Trabectedin + OlaparibAstraZenecaPhase 2
35
trabectedin + olaparibAstraZenecaPhase 1
29